weekly_roundup

BioTechSign Daily Catalyst Roundup - November 02, 2026

Top BioTechSign catalyst names today: ITCI, DCPH, BGNE, AKBA, RGNX, SRPT. FDA, clinical trial, grade-change, dilution, and sentiment signals.

BiotechSign AnalysisNovember 2, 2026

Daily Biotech Catalyst Digest: November 02, 2026

ITCI leads the current BioTechSign screen at 100.0/100 with a grade of A. The daily view combines FDA timing, clinical activity, publications, dilution risk, short interest, institutional/fund flow, and market-sentiment convergence into one research queue.

Top Catalyst Scores

TickerCompanyScoreGradeStrongest Inputs
ITCIIntra-Cellular Therapies100.0Aclinical activity 100%
DCPHDeciphera Pharmaceuticals100.0Aclinical activity 100%
BGNEBeiGene Ltd100.0Apublication signal 100%, clinical activity 100%
AKBAAkebia Therapeutics87.2Aclinical activity 92%, short interest 50%
RGNXREGENXBIO Inc86.4Apublication signal 100%, clinical activity 100%, short interest 70%
SRPTSarepta Therapeutics85.9Aclinical activity 100%, short interest 70%, dilution risk 48%

Recent Grade-Change Queue

  • SLDB (Solid Biosciences) currently grades D with a 45.8/100 catalyst score. Main inputs: publication signal 100%, short interest 70%, clinical activity 67%.
  • PRQR (ProQR Therapeutics) currently grades D with a 49.4/100 catalyst score. Main inputs: publication signal 100%, clinical activity 54%, dilution risk 46%.
  • LYEL (Lyell Immunopharma) currently grades D with a 41.7/100 catalyst score. Main inputs: publication signal 100%, dilution risk 61%, clinical activity 58%.
  • MBRX (Moleculin Biotech) currently grades D with a 39.9/100 catalyst score. Main inputs: dilution risk 92%, publication signal 80%, clinical activity 50%.
  • LRMR (Larimar Therapeutics) currently grades D with a 41.0/100 catalyst score. Main inputs: short interest 70%, dilution risk 41%, clinical activity 38%.
  • KNSA (Kiniksa Pharmaceuticals) currently grades D with a 39.7/100 catalyst score. Main inputs: clinical activity 50%, short interest 30%, dilution risk 11%.
  • IMV (IMV Inc) currently grades D with a 37.5/100 catalyst score. Main inputs: clinical activity 38%.
  • GERN (Geron Corporation) currently grades B with a 67.8/100 catalyst score. Main inputs: publication signal 100%, clinical activity 75%, dilution risk 50%.

What To Watch

Names with high clinical-trial and publication inputs deserve a pipeline read-through. Names with elevated dilution or short-interest inputs deserve tighter risk review before any catalyst trade. The purpose of this feed is to surface candidates for research, not to make buy or sell recommendations.